On November 28, 2025, iSpecimen Inc. confirmed it met Nasdaq's continued listing requirements after previously failing to comply due to insufficient stockholder equity, with a reported equity of $3,072,711. This matter is now resolved, ensuring the company's ongoing presence on the Nasdaq listing.